Samia M. Al-Muntaser‡
a,
Ahmed A. Al-Karmalawy‡*b,
Abeer M. El-Naggara,
Ali Khalil Alia,
Nour E. A. Abd El-Sattara and
Eslam M. Abbass*a
aDepartment of Chemistry, Faculty of Science, Ain Shams University, Abbassiya 11566, Cairo, Egypt. E-mail: eslammorad@sci.asu.edu.eg
bPharmaceutical Chemistry Department, Faculty of Pharmacy, Ahram Canadian University, 6th of October City, Giza 12566, Egypt. E-mail: akarmalawy@acu.edu.eg
First published on 18th April 2023
In this article, we continued our previous effort to develop new selective anticancer candidates based on the basic pharmacophoric requirements of both EGFR and VEGFR-2 inhibitors. Therefore, twenty-two novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives were designed and examined as dual EGFR/VEGFR-2 inhibitors. Besides, the previously reported antimicrobial activities of the aforementioned nuclei motivated us to screen their antibacterial and antifungal activities as well. First, the antitumor activities of the newly synthesized derivatives were evaluated against two cancer cell lines (HepG-2 and MCF-7). Notably, compounds 2a, 6a, 7a, 10b, 15a, and 18a exhibited superior anticancer activities against both HepG-2 and MCF-7 cancer cell lines. These candidates were selected to further evaluate their anti-EGFR and anti-VEGFR-2 potentialities which were found to be very promising compared to erlotinib and sorafenib, respectively. Both 10b and 2a derivatives achieved better dual EGFR/VEGFR-2 inhibition with IC50 values of 0.161 and 0.141 μM and 0.209 and 0.195 μM, respectively. Moreover, the most active 10b was selected to evaluate the exact phase of cell cycle arrest and to investigate the exact mechanism of cancer cell death whether it be due to apoptosis or necrosis. On the other hand, all the synthesized compounds were tested against Gram-positive bacteria such as S. aureus and B. subtilis as well as Gram-negative bacteria such as E. coli and P. aeuroginosa. Also, the antifungal activity was investigated against C. albicans and A. flavus strains. The findings of the antimicrobial tests revealed that most of the investigated compounds exhibited strong to moderate antibacterial and antifungal effects. Furthermore, to understand the pattern by which the investigated compounds bound to the active site, all the newly synthesized candidates were subjected to two different docking processes into the EGFR and VEGFR-2 binding sites. Besides, we tried to correlate compound 10b and the reference drugs (erlotinib and sorafenib) through DFT calculations. Finally, following the biological data of the new pyrazole, pyridine, and pyrimidine derivatives as anticancer and antimicrobial candidates, we concluded a very interesting SAR for further optimization.
Nowadays, medicinal chemists are requested to find out effective and specific chemotherapeutic agents.5,6 Such drugs are designed for inhibiting cancer cell growth by way of interacting with particular molecular targets resulting in substantial harm to the cancerous cells.7,8 However, some problems like resistance, delivery, and/or selectivity may diminish the process of drug development.9,10 Therefore, there is a great interest to understand the cellular and molecular pathways that contribute to the process of cancer initiation and/or spread.11,12
Protein kinases (PKs) constitute crucial protein families in the process of diverse disease propagation such as cancer, diabetes, and/or inflammation. Therefore, they constitute a very promising target for new drug discovery due to their prominent roles in several cellular functions like apoptosis, cell cycle, DNA damage/repair, and metabolism.13–16
Many types of tumors such as colon, breast, and ovarian subtypes resulted from the overexpression of EGFR (epidermal growth factor receptor). EGFR is a transmembrane PK receptor that is responsible for cell proliferation and/or apoptosis through different signal transduction pathways. It was recorded to be involved in the process of angiogenesis which increases the proliferation of tumor cells, invasiveness, and metastasis.17 EGFR inhibitors (e.g. erlotinib)18 are one of the most important FDA-approved drugs for cancer treatment, Fig. 1.
Fig. 1 The common pharmacophoric features of the FDA-approved drugs (erlotinib, sorafenib, and vandetanib). |
Besides, EGFR stimulation results in increasing the expression of VEGF (vascular endothelial growth factor) which is the main factor that is responsible for tumor angiogenesis after its binding to VEGFR-2 (vascular endothelial growth factor receptor-2).19 Therefore, FDA-approved VEGFR-2 inhibitors (e.g. sorafenib)20 are considered potential anticancer drugs, Fig. 1.
Due to the close relationship between the two previously discussed pathways, we can confirm that EGFR blocking will result in decreasing the endothelial expression of VEGF. Also, VEGFR-2 inhibition will potentiate the anticancer activity of EGFR inhibitors.21 Based on the above, the dual inhibition of EGFR and VEGFR-2 represents a very promising protocol for cancer treatment.22 One of the most potent dual EGFR/VEGFR-2 inhibitors is vandetanib (Fig. 1) which is an FDA-approved drug against thyroid cancer.23
According to Fig. 1, we can observe the common and greatly similar pharmacophoric features of EGFR and/or VEGFR-2 inhibitors. Both types require the presence of four pharmacophores which are the hydrophobic head, H-bond donor (for EGFRI) or H-bond donor and acceptor (for VEGFR-2I), spacer flat heteroaromatic ring, and hydrophobic tail.14,24,25
Pyrazole, pyridine, and pyrimidine systems constitute very promising scaffolds for many anticancer agents. They were previously reported as potential EGFRIs,26,27 VEGFR-2Is,28,29 and/or dual EGFR/VEGFR-2 inhibitors.30,31 Based on the aforementioned facts, we aimed to develop novel 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives as promising inhibitors against both EGFR and VEGFR-2. On the other hand, the previously mentioned moieties showed apparent antimicrobial activities32,33 which encourages us to screen the antibacterial and antifungal activities of the newly designed targets.
Briefly, the principal pharmacophoric features of EGFR inhibitors (Fig. 2) were identified as follows:2
(a) Hydrophobic head to bind the hydrophobic region I.
(b) H-bond donor in the spacer region.
(c) Flat heteroaromatic ring to bind the adenine binding pocket.
(d) Hydrophobic tail to bind the hydrophobic region I.
However, the pharmacophoric features of VEGFR-2 inhibitors (Fig. 2) were identified as:34
(a) Flat aromatic ring to occupy the hinge region.
(b) Spacer moiety.
(c) Both the H-bond donor and acceptor to bind the DFG motif.
(d) Hydrophobic moiety to bind the allosteric hydrophobic region.
Therefore, the new design is based on the introduction of the thiophene ring to act as a hydrophobic tail and bind the hydrophobic region II of EGFR or the hinge region of VEGFR-2. Besides, the pyridine or pyrazole moiety to bind the adenine binding pocket of EGFR or to act as a spacer for the VEGFR-2 receptor. Moreover, different functional groups were introduced as H-bond donors and/or acceptors to form H-bonds in the spacer region of EGFR or the DFG-motif region of VEGFR-2. Finally, a p-hydroxyphenyl ring was added to occupy the hydrophobic region I of EGFR or the allosteric hydrophobic region of VEGFR-2.
Accordingly, the main aim of this new design is to target both EGFR and VEGFR-2 receptors even if not all the pharmacophoric features are present typically in the new candidates. The atypical design of some new derivatives may give them adequate flexibility to bind both receptors which may be advantageous.
On the other hand, the previously reported antibacterial and/or antifungal activities of the pyrazole, pyridine, and pyrimidine derivatives motivated us to further screen the antibacterial and antifungal activities of the newly synthesized candidates.
Thus, we synthesized a polarized system as 1-(aryl)-3-(thiophen-2-yl)prop-2-en-1-one “chalcone”, and then accomplished by ring closure to afford novel heterocyclic compounds (pyridine and pyrazole). Claisen–Schmidt condensation38,39 of substituted ketone derivatives with thiophene-2-carboxaldehyde afforded chalcones 1a and 1b (Scheme 1).
According to the previously reported methods, the derivatives were prepared at a high yield. The chalcone derivatives and suitable nucleophile compounds were heated under reflux conditions and utilized for the synthesis of various pyrimidine and pyrazole derivatives. All the target compounds 1a–20a were characterized using spectral data such as 1H NMR, mass, and IR spectroscopy. Moreover, the purity of the previously mentioned derivatives was confirmed by elemental analyses as depicted in the ESI.†
The spectral data of chalcone 1b laid a strong foundation for a confirmation of the chemical structure and stereochemistry of 1b. The IR spectrum exhibited an absorption band at 1655 cm−1 characteristic of functionalities of CO. Moreover, the 1H NMR spectrum of chalcone 1b indicated the presence of two doublets at 7.57 and 7.92 ppm corresponding to β and α protons of CC, respectively, with J = 14.8 Hz.
In this paper, we study the behavior of chalcones 1a, 1b towards some C- and N-nucleophilic reagents. So, we synthesized new heterocyclic compounds by refluxing chalcone 1a and or 1b in ethanol in the presence of ammonium acetate with malononitrile, ethyl acetoacetate, and diethyl malonate afford the pyridine derivatives 2a–6a respectively. In the case of ethyl cyanoacetate addition of one molecule afforded compound 5a while the addition of two molecules afforded compound 6a. Their structures were confirmed by recording their spectral data. For compounds 2a and 2b. The IR spectrum showed bands at the range 3223–3362 and 2200–2213 cm−1 attributed to NH2 and CN groups respectively. The 1H NMR spectra of compounds 2a and 2b exhibited a singlet signal at δ 7.15 and 6.91 attributed to NH2 protons, respectively.
However, the IR spectrum of compound 3a showed bands at 3107 and 1695 cm−1 attributed to NH and CO groups respectively. The 1H NMR spectrum exhibited a singlet at δ 2.50 and 9.86 ppm, attributed to CH3–CO and OH protons, respectively. For compound 4a its IR spectra exhibited bands at 3170, 1725, and 1675 cm−1 attributed to NH and 2 CO groups. The 1H NMR spectrum exhibited signals at δ 1.11, 3.91, and 7.19 ppm, attributed to CH3, CH2, and NH proton, respectively. For compound 5a its IR spectra exhibited bands at 3301, 2216, and 1636 cm−1 attributed to OH, CN, and CN groups, respectively. The 1H NMR spectrum exhibited a singlet at δ 10.22, and 12.48 ppm, attributed to two OH protons. The spectral data of compound 6a confirmed the expected structure. IR spectra exhibited bands at 3369, 2217, and 1683 cm−1 attributed to NH, CN, and CO groups. The 1H NMR spectrum exhibited a singlet at δ 6.47 and 9.81 ppm, attributed to NH2, and NH proton, respectively.
Moreover, the reaction of α,β-unsaturated ketones with hydrazine hydrate and its derivatives (Scheme 2) for synthesis, pyrazolines is one of the most convenient methods. Pyrazoline derivatives 7a–9b were synthesized by the reaction of chalcones 1a and/or 1b with hydrazine hydrate in ethanol, in glacial acetic acid and phenylhydrazine, respectively via aza Michael addition of hydrazine on chalcone 1b, followed by a 5-exo-trig ring cyclization and dehydration. Elemental analyses, IR, and 1H NMR spectra supported the structure confirmation of compounds 7a–9b (Scheme 2).
The IR spectra of compounds 7a–9b showed bands at the range 1606–1636 cm−1 that account for the formation of the CN bond. In addition, compound 8b showed a band at 1667 cm−1 attributed to CO. The appearance of CH2 proton at 2.82, 3.27, 3.24 ppm in the 1H NMR spectra of compounds 7a–9b respectively, confirmed the formation of the pyrazole ring, in addition to the appearance of signals at δ 5.05, 5.84 and 5.86 for compounds 7a–9b, respectively attributed to CH proton of pyrazole ring. Also, compound 8b showed a singlet signal at 2.48 ppm accounts for the CH3 protons.
Similarly, the reaction of chalcones 1a, b with thiosemicarbazide in two different conditions afforded pyrazole carbothioamide derivative, the first condition is refluxing of chalcone 1a in ethanolic solution in the presence of a catalytic amount of acetic acid afforded compound 10a the second condition is refluxing of chalcone 1b in ethanolic sodium hydroxide solution afforded compound 10b (Scheme 3).
Alkylation of both compounds 10a and 10b by 2,3-dichloroquinoxalin and phenacyl bromide afforded pyrazole derivatives 12a and 12b, respectively. Refluxing of chalcone 1a with guanidine hydrochloride in ethanolic sodium hydroxide solution afforded compound 11a which condensed with salicylaldehyde in ethanol with a catalytic amount of piperidine afforded pyrimidine derivative 13a (Scheme 3).
The IR spectra of compounds 10a, 10b, and 11a showed bands at the range 3145–3343 cm−1 that account for the presence of NH2 and showed bands at the range 1636–1639 cm−1 that account for the formation of CN. In addition, compound 12b showed bands at 1668 and 2849 cm−1 attributed to CO and CH-aliphatic, respectively. The 1H NMR spectra of compounds 10a and 11a showed the appearance of singlet signals at 6.88, 6.99, and 7.65 ppm, attributed to CH protons of pyrazole and pyrimidine rings, respectively. In addition, compound 12b showed a singlet signal at 4.82 attributed to CH2 protons. Compound 13a showed singlet signals at 7.51 and 7.56 attributed to CH of pyrimidine and CHN.
Furthermore, to study the reactivity of pyrazole ring towards the electrophilic reagents as 7a with phenyl isothiocyanate, ethyl chloroacetate, and 2-chloro-N-(4-sulfamoylphenyl)acetamide in different conditions afforded pyrazole derivatives 14a–16a (Scheme 4).
The spectral data were in agreement with the predicted structure of the compounds. For compound 15a, the IR spectrum showed bands at 1731 cm−1 attributed to the CO group. Its 1H NMR exhibited triplet and quartet signals at 1.02 and 4.09 ppm attributed to CH3 and CH2 protons. For compound 16a, the IR spectrum showed bands at 1694 cm−1 attributed to the CO group. Its 1H NMR exhibited signals at 5.15 ppm attributed to CH2 protons of the acetamide group.
On the other hand, in extension to our previous work on the PTC alkylation of 1,3-disubstituted-2-pyrazolin-5-ones40,41 we have studied here the reactivity of pyrazole derivative towards PTC alkylation and acylation in the presence or absence of CS2.
Alkylation of pyrazole derivative (7a) by ethylchloroacetate, benzoyl chloride, chloroacetic acid, and chloroacetyl chloride in the presence of carbon disulfide under liquid/solid PTC reaction conditions afforded pyrazole-1-carbonothioyl 17a–20a (Scheme 5).
The IR spectra of 17a–20a showed bands at 1696, (1696, 1736), 1692, and (1746, 1694) cm−1 attributed to CO groups, respectively. For more conformation to the predicted structure. The 1H NMR of 17a exhibited signals at 4.06 ppm attributed to CH2 protons of the ester group. The CH2 group of acid present in compound 19a exhibited a singlet signal at 3.60 ppm. However, the CH2 of acetyl chloride in compound 20a exhibited a singlet signal at 4.35 ppm.
The reaction proceeds via the nucleophilic addition of pyrazole at N− to CS2 followed by simultaneous N-alkylation of the intermediate thiocarbamic acid. The suggested mechanism is represented in the ESI.†
Comp. | Cell lines (IC50 μM) | |
---|---|---|
HepG-2 | MCF-7 | |
1a | 87.56 ± 4.2 | 82.45 ± 4.2 |
1b | 84.16 ± 4.2 | >100 |
2a | 8.42 ± 0.6 | 9.59 ± 0.8 |
2b | 59.47 ± 3.1 | 55.46 ± 3.2 |
3a | 53.21 ± 3.1 | 48.35 ± 2.7 |
4a | 44.45 ± 2.6 | 41.22 ± 2.4 |
5a | 43.03 ± 2.5 | 38.37 ± 2.5 |
6a | 16.24 ± 1.3 | 19.12 ± 1.6 |
7a | 8.13 ± 0.6 | 3.54 ± 0.2 |
8b | 74.28 ± 3.5 | 72.64 ± 3.9 |
9b | 48.11 ± 2.7 | 67.33 ± 3.7 |
10a | 39.07 ± 2.4 | 23.72 ± 1.7 |
10b | 13.81 ± 1.1 | 23.24 ± 1.8 |
11a | 52.94 ± 2.9 | 61.08 ± 3.4 |
12a | 74.73 ± 3.9 | 65.03 ± 3.6 |
12b | 29.20 ± 2.1 | 35.95 ± 2.3 |
13a | 34.76 ± 2.3 | 42.75 ± 2.6 |
14a | 69.20 ± 3.6 | 54.81 ± 3.1 |
15a | 21.38 ± 1.5 | 9.48 ± 0.7 |
16a | 34.53 ± 2.2 | 29.06 ± 2.0 |
17a | 62.41 ± 3.3 | 36.87 ± 2.2 |
18a | 12.94 ± 1.0 | 6.92 ± 0.5 |
19a | 28.20 ± 1.9 | 14.69 ± 1.2 |
20a | 67.41 ± 3.5 | 56.19 ± 3.3 |
DOX | 4.50 ± 0.2 | 4.17 ± 0.2 |
(a) Pyrazole-based moieties:
• Dihydropyrazole derivatives were more active than pyrazole ones against the two cancer cell lines. Dihydropyrazole candidates which do not contain N-substitution like 7a showed very strong activities against both HepG-2 and MCF-7 more than the N-substituted dihydropyrazoles.
• N-Substituted dihydropyrazole with CH2–CO-attracting group like 15a showed very strong activity against MCF-7 and moderate activity against HepG-2 while N-substituted dihydropyrazole with CH2–CO-donating group like 16a represented moderate activities against both cell lines.
• On the other hand, N-substituted dihydropyrazole with CS-S-G side chains as in compounds 17a–20a have higher activities on the MCF-7 than the HepG-2 cell line. They showed very strong to weak activities depending on the nature of the group (G) as follows:
(i) If G is an aliphatic acid derivative like 18a, it achieved very strong activity against MCF-7 and strong activity against HepG-2.
(ii) However, if G is a benzoyl derivative like 19a, it expressed strong activity towards MCF-7 and moderate activity towards HepG-2.
(iii) Besides, if G is an aliphatic ester derivative like 17a, it showed moderate activity against MCF-7 and weak activity with HepG-2.
(iv) While, if G is an acetyl derivative like 20a, it showed weak activity with both cell lines.
• Furthermore, the N-substituted pyrazole derivatives with CS-NH2 side chain like 10a and 10b showed strong to moderate activities depending on the substituted phenyl ring attached to pyrazole as follow:
(i) In the case of the activated ring like 4-hydroxy benzene in compound 10a, it showed moderate activities with both cell lines.
(ii) While, in the case of the deactivated ring like dichlorobenzene in compound 10b, it showed strong activity on HepG-2 and moderate activity on MCF-7.
(b) Pyridine-based moieties:
• Pyridine analogs containing the NH2 group in the alpha position to the attracting CN group like compounds 2a and 6a achieved very strong and strong activities against both cancer cell lines. The fused pyridopyridine derivative 6a showed lower activities than the pyridine derivative 2a.
• On the other hand, pyridines containing the OH group in the alpha position to the attracting groups (COCH3, COOEt, and CN) in 3a, 4a, and 5a compounds, respectively, showed moderate activities against the two cancer cell lines.
(c) Pyrimidine-based moieties:
• Pyrimidine derivatives (11a and 13a) showed moderate and weak anticancer activities depending on the substitution in position 2 of pyrimidine as follows:
(i) If position 2 contains a donating group like NH2 in compound 11a, it showed moderate antitumor activities on both cancer cell lines.
(ii) While, when NH2 functional group was condensed with the aromatic aldehyde like 13a, the activity decreased on both cell lines.
Fig. 5 Induction of apoptosis in HepG-2 cells by 10b shows both apoptotic (total, early, and late) and necrotic cell death. |
Comp. | Gram-positive bacteria | Gram-negative bacteria | Fungi | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
S. aureus | B. subtilis | E. coli | P. aeuroginosa | C. albicans | A. flavus | |||||||
Diameter of inhibition zone (mm) | % Activity index | Diameter of inhibition zone (mm) | % Activity index | Diameter of inhibition zone (mm) | % Activity index | Diameter of inhibition zone (mm) | % Activity index | Diameter of inhibition zone (mm) | % Activity index | Diameter of inhibition zone (mm) | % Activity index | |
1a | NA | — | NA | — | NA | — | NA | — | 3 | 10.7 | NA | — |
1b | NA | — | NA | — | NA | — | NA | — | NA | — | NA | — |
2a | 10 | 55.5 | 15 | 68.2 | 9 | 42.8 | 12 | 63.1 | 18 | 64.3 | 12 | 46.1 |
2b | 9 | 50.0 | 14 | 63.6 | 8 | 38.1 | 11 | 57.9 | 17 | 60.7 | 10 | 38.5 |
3a | 5 | 27.8 | 9 | 40.9 | 4 | 19.0 | 6 | 31.6 | 11 | 39.3 | 10 | 38.5 |
4a | 6 | 33.3 | 10 | 45.4 | 5 | 23.8 | 8 | 42.1 | 13 | 46.4 | 11 | 42.3 |
5a | 6 | 33.3 | 10 | 45.4 | 5 | 23.8 | 10 | 52.6 | 14 | 50.0 | 8 | 30.8 |
6a | 5 | 27.8 | 9 | 40.9 | 4 | 19.0 | 7 | 36.8 | 12 | 42.8 | 8 | 30.8 |
7a | 15 | 83.3 | 19 | 86.4 | 12 | 57.1 | 17 | 89.5 | 23 | 82.1 | 18 | 69.2 |
8b | 3 | 16.7 | 7 | 31.8 | NA | — | 4 | 21.0 | 9 | 32.1 | 5 | 19.2 |
9b | NA | — | 6 | 27.3 | NA | — | NA | — | 8 | 28.6 | 3 | 11.5 |
10a | 9 | 50.0 | 13 | 59.1 | 8 | 38.1 | 12 | 63.1 | 13 | 46.4 | 11 | 42.3 |
10b | 12 | 66.7 | 17 | 77.3 | 9 | 42.8 | 13 | 68.4 | 20 | 71.4 | 14 | 53.8 |
11a | 7 | 38.9 | 10 | 45.4 | 6 | 90.5 | 11 | 57.9 | 11 | 39.3 | 7 | 26.9 |
12a | NA | — | 5 | 22.7 | NA | — | 3 | 15.8 | 6 | 21.4 | NA | — |
12b | 7 | 38.9 | 12 | 54.5 | 5 | 23.8 | 8 | 42.1 | 15 | 53.6 | 10 | 38.5 |
13a | 14 | 77.8 | 18 | 81.8 | 13 | 61.9 | 15 | 78.9 | 21 | 75.0 | 16 | 61.5 |
14a | 4 | 22.2 | 8 | 36.4 | 3 | 14.3 | 6 | 31.6 | 7 | 25.0 | 5 | 19.2 |
15a | 10 | 55.5 | 15 | 68.2 | 9 | 42.8 | 14 | 73.7 | 18 | 64.3 | 15 | 57.7 |
16a | 8 | 44.4 | 11 | 50.0 | 7 | 33.3 | 11 | 57.9 | 15 | 53.6 | 12 | 46.1 |
17a | 6 | 33.3 | 11 | 50.0 | 7 | 33.3 | 9 | 47.4 | 10 | 35.7 | 8 | 30.8 |
18a | 13 | 72.2 | 17 | 77.3 | 10 | 47.6 | 15 | 78.9 | 20 | 71.4 | 16 | 61.5 |
19a | 10 | 55.5 | 14 | 63.6 | 9 | 42.8 | 12 | 63.1 | 16 | 57.1 | 13 | 50.0 |
20a | 3 | 16.7 | 6 | 27.3 | NA | — | 4 | 21.0 | 9 | 32.1 | 7 | 26.9 |
Gentamicin | 18 | 100 | 22 | 100 | 21 | 100 | 19 | 100 | — | — | — | — |
Ketoconazole | — | — | — | — | — | — | — | — | 28 | 100 | 26 | 100 |
The findings of the antimicrobial test revealed that most of the investigated compounds exhibited strong to moderate antibacterial effects towards the Gram-positive and Gram-negative bacteria. With regards to the antifungal activity, all the synthesized compounds exhibited good activities against both Candida albicans and Aspergillus fumigatus except 1a, 1b, and 12a.
The antimicrobial activities based on the main nuclei (pyrazole-based, pyridine-based, and pyrimidine-based moieties) showed the following results:
(a) Pyrazole-based moieties
• Dihydropyrazole derivatives were more active than pyrazole derivatives. The NH-dihydropyrazole (7a) showed very strong activities with all six microbes.
• However, N-substituted dihydropyrazole showed activities from very strong to weak depending on the type of substituent as follows:
(i) N-Substitution with CS-S-benzoyl like 18a got moderate activity with E. coli and very strong activity with the other five tested microbes.
(ii) While N-substitution with CS-S-aliphatic acid like 19a achieved moderate activities with all six microbes.
(iii) But other N-substituted dihydropyrazoles with CS-S-ester and CS-S-acetyl derivatives like 17a and 20a respectively showed weak activities with all the six tested microbes.
(iv) Moreover, N-substitution with CH2–CO acquired strong to moderate activities based on the type of CO; if N-substituted with CH2–CO (ester) like 15a, it showed strong activities with B. subtilis, P. aeuroginosa, and C. albicans, and showed moderate activities with other tested microbes.
(v) While N-substitution with CH2–CO (amide) like 16a showed weak activity with E. coli and moderate activities with the other five microbes.
• On the other hand, all pyrazole derivatives showed weak activities with all tested microbes except N-substituted pyrazole with CS-NH2 like 10a and 10b achieved strong to moderate activities depending on the type of benzene derivative linked to position 3 of pyrazole:
(i) In the case of the activated ring like 4-hydroxyphenyl as in 10a, it showed moderate activities with all tested microbes.
(ii) While, in the case of the deactivated ring like 3,4-dichlorophenyl as in 10b, it showed very strong activity with S. aureus, B. subtilis, P. aeuroginosa, and C. albicans and moderate activities with other tested microbes.
(b) Pyridine-based moieties
• Pyridine derivatives which contain NH2 in the alpha position to N-heteroatom-like compounds 2a and 2b showed strong activities against B. subtilis, P. aeuroginosa, and C. albicans and got moderate activities with the other tested microbes.
• However, pyridine derivatives that contain CO in the alpha position to N-heteroatom as in compounds 3a–6a showed weak activities against all tested microbes.
(c) Pyrimidine-based moieties
• Pyrimidine derivatives like 11a and 13a showed very strong to moderate activities depending on the type of substituent in position 2 of the pyrimidine ring, where:
(i) If position 2 contains a donating group like NH2 as in 11a, it showed very strong activity with E. coli, weak activity with A. flavus, and moderate activity with the other microbes.
(ii) While, when NH2 condensed with aromatic aldehyde as in compound 13a, it achieved very strong activities with all tested microbes.
Compound | EGFR | VEGFR-2 | ||
---|---|---|---|---|
Docking score (kcal mol−1) | RMSD | Docking score (kcal mol−1) | RMSD | |
2a | −6.20 | 1.44 | −6.08 | 1.57 |
6a | −6.52 | 0.81 | −6.01 | 1.47 |
7a | −5.88 | 1.15 | −5.15 | 2.13 |
10b | −6.45 | 1.42 | −6.44 | 1.44 |
15a | −6.96 | 1.98 | −6.17 | 1.23 |
18a | −7.47 | 1.86 | −6.86 | 1.62 |
HYZ | −7.81 | 0.99 | — | — |
GIG | — | — | −9.54 | 1.29 |
First, two validation processes were carried out to confirm the validity of the MOE program in getting accurate docking results. This was established by redocking each one of the two co-crystallized inhibitors (HYZ and GIG) of EGFR and VEGFR-2 receptors, respectively. The obtained low values of RMSD (0.99 and 1.29 Å, respectively) which represent the root mean square deviation between the native and redocked poses of the co-crystallized inhibitor ensured the valid performance.43,44 Besides, the most active dual EGFR/VEGFR-2 inhibitors (2a and 10b) were selected for further investigations compared to the native inhibitors (HYZ and GIG) of EGFR and VEGFR-2, respectively (Table 4).
HYZ inside the binding pocket of the EGFR receptor (S = −7.80 kcal mol−1 and RMSD = 1.33 Å) was found to form one pi–cation bond with LYS745 at 4.16 Å and two pi–H bonds with VAL726 at 4.29 and 4.64 Å, respectively. However, GIG inside the binding pocket of the VEGFR-2 receptor (S = −9.54 kcal mol−1 and RMSD = 1.29 Å) formed two H-bonds with GLU833 at 2.90 and 2.79 Å, respectively, one H-bond with ASP1044 at 2.95 Å, and one pi–H bond with LEU838 at 4.04 Å.
However, compound 2a inside the binding pocket of the EGFR receptor (S = −6.20 kcal mol−1 and RMSD = 1.44 Å) was found to form two H-bonds with MET793 and LYS745 amino acids at 3.16 and 3.74 Å, respectively. Besides, it formed two pi–H bonds with LYS745 at 4.51 and 4.60 Å, and one pi–H bond with VAL726 at 3.77 Å. On the other hand, its binding score within the active site of the VEGFR-2 receptor was −6.08 kcal mol−1 (RMSD = 1.58 Å). It showed the formation of three H-bonds with GLU883, GLU915, and CYS917 at 3.04, 2.80, and 3.65 Å, respectively. It also bound LEU 838 with a pi–H bond at 3.65 Å.
On the other hand, compound 10b inside the binding pocket of the EGFR receptor (S = −6.45 kcal mol−1 and RMSD = 1.42 Å) formed three H-bonds with ASN842, LEU788, and LYS745 amino acids at 3.12, 3.22, and 3.52 Å, respectively. Moreover, it formed a pi–H bond with VAL726 at 3.82 Å. Furthermore, it showed the formation of one H-bond with ASP1044 at 2.92 Å and one pi–H bond with VAL896 at 3.73 Å, within the active site of the VEGFR-2 receptor (S = −6.44 kcal mol−1 and RMSD = 1.44 Å).
In the present section, we tried to correlate compound 10b and the reference drugs, erlotinib, and sorafenib. Density functional theory (DFT) calculations were performed by using the Gaussian 09W program.45 The optimized structures of 10b, erlotinib, and sorafenib are represented in Fig. 7.
Fig. 7 The optimized structures and HOMO–LUMO charge density maps of compound 10b and the reference drugs (erlotinib and sorafenib) were calculated at the B3LYP-6-31G+(d,p) level of theory. |
Moreover, the LUMO energy characterizes the sensitivity of the molecule to a nucleophilic attack, and the HOMO energy characterizes the susceptibility of a molecule to an electrophilic attack. Electronegativity (χ) is the parameter that reflects the ability of a molecule not to let out its electrons. Global softness (S) expresses the resistance of a system to the change in its number of electrons. The theoretical global parameters calculated at the same level of theory are listed in Table 5. The energy gap (Eg) between HOMO and LUMO characterizes the molecular chemical stability and molecular electrical transport properties because it is a measure of electron conductivity.
Property | Compound | ||
---|---|---|---|
10b | Erlotinib | Sorafenib | |
EHOMO (eV) | −6.351 | −5.804 | −6.231 |
ELUMO (eV) | −2.098 | −1.605 | −1.673 |
Energy gap = |EHOMO − ELUMO| eV | 4.253 | 4.198 | 4.558 |
Ionization potential (I = −EHOMO) eV | 6.351 | 5.804 | 6.231 |
Electron affinity (A = −ELUMO) eV | 2.098 | 1.605 | 1.673 |
Electronegativity χ = (I + A)/2 eV | 4.224 | 3.704 | 3.952 |
Chemical potential p = −χ eV | −4.224 | −3.704 | −3.952 |
Chemical hardness (η = (I − A)/2) eV | 2.127 | 2.099 | 2.279 |
Chemical softness (S = 1/2η) eV | 0.235 | 0.238 | 0.219 |
From the data in Table 5, the order of increasing EHOMO is 10b > sorafenib > erlotinib while the order of decreasing ELUMO is erlotinib < sorafenib < 10b. From the order of EHOMO and ELUMO, compound 10b has the highest nucleophilicity and electrophilicity.
Also, analyzing the calculated values of hardness (η) and softness (S) for the investigated compounds revealed the donor–acceptor behavior of the studied molecules. Back to the energies of HOMO and LUMO, the order of increasing the energy gap is sorafenib > 10b > erlotinib, so sorafenib is the hardest one (large energy gap) while erlotinib (small energy gap) represents the softest molecule (c.f. Fig. 7). Hence, the most polarizable (softest) with easier charge transfer and highest chemical reactivity molecule is erlotinib with S = 0.238 eV, while the least polarizable molecule (hardest) is sorafenib with η = 2.279 eV.
Moreover, the ionization potential (I) eV which is also related to the donating properties of the molecules (the higher the ionization potential value the lower the donation ability of the molecule) was used to evaluate the tendency of molecules to be oxidized. It showed that the order of increasing of the most probable molecule to act as a reducing agent is erlotinib < sorafenib < 10b.
Furthermore, the escaping tendency of an electron is measured by its chemical potential p (eV) and it is also related to its electronegativity. As p increases, the tendency of a molecule to lose an electron increases. Electronegativity (χ) represents the molecular ability to attract electrons, the (χ) values displayed in Table 5 show that 10b > sorafenib > erlotinib in electronegativity and erlotinib > sorafenib > 10b in chemical potential (P).
The chemical hardness and chemical potential are the main factors of the overall reactivity of the molecule and are the most fundamental descriptors of charge transfer during a chemical reaction.
Fig. 8 Anticancer and antimicrobial activities of the novel pyrazole, pyridine, and pyrimidine candidates related to their chemical structures. |
Generally, the 4-OH substitution on the side phenyl ring was found to be superior to the 3,4-diCl substitution regarding both the anticancer and antimicrobial activities.
• Regarding the anticancer activity: the descending order of activity was found to be (dihydropyrazole > N-substituted dihydropyrazole > pyridine > pyrimidine derivatives).
(i) Compound 7a (R1 = –H) with dihydropyrazole nucleus was found to be the most active against both HepG-2 and MCF-7 cancer cell lines.
(ii) However, the N-substituted dihydropyrazole derivatives achieved very strong to moderate antitumor activities according to the R1 substitution as follows: –CH2COOC2H5 (15a) > –CH2CONHphSO2NH2 (16a) > –CSSCOph (18a) > –CSSCH2COOH (19a) > –CSSCH2COOC2H5 (17a) > –CSSCOCH2Cl (20a) > –CSNH2 (10a, 10b).
(iii) Besides, the compounds containing the pyridine nucleus exhibited lower activity than the dihydropyrazole and N-substituted dihydropyrazole nuclei. The pyridine candidates showed very strong to moderate anticancer activities according to both R2 and R3 substituents as follows: –CN and –NH2 (2a) > fused pyridopyridine (6a) > –COCH3 and –CO (3a) ≡ –COOC2H5 and CO (4a) ≡ –CN and –OH (5a), respectively.
(iv) Moreover, the pyrimidine moiety derivatives were the lowest anticancer with moderate to weak activities regarding the R4 substituent as follow: –NH2 (11a) > –NCHphOH (13a).
• Regarding the antimicrobial activity: the descending order of activity was noted to be (dihydropyrazole > N-substituted dihydropyrazole > pyrimidine > pyridine derivatives).
(i) Again, compound 7a (R1 = –H) with dihydropyrazole nucleus exhibited superior antibacterial and antifungal activities.
(ii) On the other hand, the N-substituted dihydropyrazole derivatives achieved strong to moderate antimicrobial activities according to the R1 substitution as follows: –CSSCOph (18a) > –CH2COOC2H5 (15a) > –CSSCH2COOH (19a) > –CSNH2 (2,3-diClph) (10b) > –CSNH2 (4-OHph) (10a) > –CH2CONHphSO2NH2 (16a) > –CSSCH2COOC2H5 (17a) > –CSSCOCH2Cl (20a).
(iii) Controversy, the pyrimidine moiety derivatives showed better antimicrobial activities than the pyridine ones. The order of decreasing the antimicrobial potentials was according to the R4 substituent as follows: –NCHphOH (13a) > –NH2 (11a).
(iv) Furthermore, the pyridine-containing compounds exhibited lower antimicrobial activities according to both R2 and R3 substituents as follows: –CN and –NH2 (4-OHph) (2a) > –CN and –NH2 (2,3-diClph) (2b) > –CN and –OH (5a) > –COOC2H5 and CO (4a) > fused pyridopyridine (6a) > –COCH3 and –CO (3a).
Yield 55%; as yellow crystal; mp 85 °C (EtOH); IR (cm−1) ν: 1655 (CO); 1H-NMR: 7.21 (d, d, 1H, CH thiophene ring), 7.57 (d, 1H, CH-olefinic), 7.73 (d, 1H, CH of benzene ring), 7.81 (s, 1H, CH benzene ring), 7.82 (d, 1H, CH of benzene ring), 7.92 (d, 1H, CH olefinic), 8.04 (d, 1H, CH of thiophene ring), 8.07 (d, 1H, CH of thiophene ring); MS (m/z) (%): 283 (M+, 15), 117 (100). Anal. calcd for C13H8Cl2OS (283.17): C, 55.14; H, 2.85; found: C, 54.89; H, 2.74.
Yield 67%; yellow crystal; mp 200 °C (EtOH); IR (cm−1) ν: 3400 (OH), 2216 (CN), 1636 (CN); 1H-NMR: 6.81–8.01 (m, 8H, Ar-H), 10.22 (s, 1H, OH of benzene ring), 12.48 (s, 1H, OH of pyridine ring). Anal. calcd for C16H10N2O2S (294.33): C, 65.29; H, 3.42; N, 9.52; found: C, 65.18; H, 3.48; N, 9.60.
Yield 77%; yellow crystal; mp 260 °C (EtOH); IR (cm−1) ν: 3480 (OH), 3369 (NH), 2217 (CN), 1683 (CO), 1649 (CN); 1H-NMR: 6.47 (s, 2H, NH2), 6.84–8.05 (m, 7H, Ar-H), 7.07 (s, 1H, CH of pyridine ring), 9.81 (s, 1H, NH), 12.51 (s, 1H, OH). Anal. calcd for C19H12N4O2S (360.39): C, 63.32; H, 3.36; N, 15.55; found: C, 63.09; H, 3.40; N, 15.48.
Yield 83%; white crystal; mp 100–102 °C (EtOH); IR (cm−1) ν: 3290 (NH), 2879 (CH aliphatic), 1606 (CN); 1H-NMR: 2.82 (d, d, 2H, CH2 of pyrazole ring), 5.05 (d, d, 1H, CH of pyrazole ring), 6.77–7.47 (m, 7H, Ar-H), 9.67 (s, 1H, NH). Anal. calcd for C13H12N2OS (244.31): C, 63.91; H, 4.95; N, 11.47; found: C, 63.72; H, 4.84; N, 11.36.
Yield 75%; brown crystal; mp 160 °C (EtOH); IR (cm−1) ν: 2926 (CH-aliphatic), 1667 (CO), 1636 (CN); 1H-NMR: 2.48 (s, 3H, CH3–CO), 3.27 (d, d, 2H, CH2 of pyrazole ring), 5.84 (d, d, 1H, CH of pyrazole ring), 6.91–7.99 (m, 6H, Ar-H). Anal. calcd for C15H12Cl2N2OS (339.23): C, 53.11; H, 3.57; N, 8.26; found: C, 52.89; H, 3.50; N, 8.35.
Yield 81%; beige crystal; mp 130 °C (EtOH); IR (cm−1) ν: 2867 (CH aliphatic), 1593 (CN); NMR: 3.24 (d, d, 2H, CH2 of pyrazole ring), 5.86 (d, 1H, CH of pyrazole ring), 6.75–7.93 (m, 11H, Ar-H). Anal. calcd for C19H14Cl2N2S (373.30): C, 61.13; H, 3.78; N, 7.50; found: C, 60.87; H, 3.66; N, 7.43.
Yield 73%; green crystal; mp 195–197 °C (EtOH); IR (cm−1) ν: 3406 (OH), 3343, 3268 (NH2), 2921 (CH aliphatic), 1636 (CN); 1H-NMR: 7.37–8.51 (m, 7H, Ar-H), 6.88 (s, 1H, CH of pyrazole ring), 10.03 (s, 2H, NH2), 10.42 (s, 1H, OH). Anal. calcd for C14H11N3OS2 (301.38): C, 55.79; H, 3.68; N, 13.94; found: C, 55.58; H, 3.72; N, 14.05.
Yield 65%; bale yellow crystal; mp 260 °C (EtOH); IR (cm−1) ν: 3259, 3145 (NH2), 1639 (CN), 1596 (CC), 1297 (CS); 1H-NMR: 6.22–8.17 (m, 6H, Ar-H), 6.99 (s, 1H, CH of pyrazole ring), 7.73 (s, 2H, NH2); MS (m/z) (%): 354 (M+, 10), 109 (100). Anal. calcd for C14H9Cl2N3S2 (354.27): C, 47.47; H, 2.56; N, 11.86; found: C, 47.30; H, 2.49; N, 11.76.
Yield 76%; yellow crystal; mp 180 °C (EtOH); IR (cm−1) ν: 3290 (OH), 3200 (NH2), 1636 (CN); 1H-NMR: 6.91 (s, 2H, NH2), 6.89–8.01 (m, 7H, Ar-H), 7.65 (s, 1H, CH of pyrimidine ring), 10.43 (s, 1H, OH); MS (m/z) (%): 269 (M+, 10), 74 (100). Anal. calcd for C14H11N3OS (269.32): C, 62.44; H, 4.12; N, 15.60; found: C, 62.23; H, 4.19; N, 15.51.
Yield 78%; brown crystal; mp 250–252 °C (EtOH); IR (cm−1) ν: 3444 (OH), 1664 (CN); 1H-NMR: 6.90–7.98 (m, 11H, Ar-H), 7.17 (s, 1H, CH of pyrazole ring), 9.00 (s, 1H, OH). Anal. calcd for C22H13N5OS2 (427.50): C, 61.81; H, 3.07; N, 16.38; found: C, 61.69; H, 3.00; N, 16.26.
Yield 63%; green crystal; mp 160 °C (EtOH); IR (cm−1) ν: 3112 (NH), 2849 (CH aliphatic), 1668 (CO), 1653 (CN); 1H-NMR: 4.82 (s, 2H, CH2–CO), 5.81 (s, 1H, NH), 6.85 (m, 11H, Ar-H), 6.86 (s, 1H, CH of pyrazole ring). Anal. calcd for C22H15Cl2N3OS2 (472.40): C, 55.94; H, 3.20; N, 8.90; found: C, 55.75; H, 3.12; N, 8.79.
Yield 51%; brown crystal; mp 133–135 °C (EtOH); IR (cm−1) ν: 3417 (OH), 1639 (CN); 1H-NMR: 6.84–8.02 (m, 11H, Ar-H), 7.51 (s, 1H, CH of pyrimidine ring), 7.56 (s, 1H, CHN), 10.44 (s, 1H, OH), 10.44 (s, 1H, OH). Anal. calcd for C21H15N3O2S (373.43): C, 67.54; H, 4.05; N, 11.25; found: C, 67.39; H, 4.00; N, 11.34.
Yield 81%; white crystal; mp 245–247 °C, EtOH; IR (cm−1) ν: 3323 (OH), 3182 (NH), 3028 (CH aliphatic), 1604 (CN); 1H-NMR: 3.34 (d, d, 2H, CH of pyrazole), 3.83 (d, d, 1H, CH of pyrazole ring), 7.14–7.88 (m, 12H, Ar-H), 7.04 (s, 1H, NH), 10 (s, 1H, OH). Anal. calcd for C20H17N3OS2 (379.50): C, 63.30; H, 4.52; N, 11.07; found: C, 63.08; H, 4.59; N, 11.17.
Yield 75%; brown crystal; mp 65 °C, EtOH; IR (cm−1) ν: 3254 (OH), 1731 (CO), 1604 (CN); 1H-NMR: 1.02 (t, 3H, CH3), 2.91 (s, 2H, CH2), 3.59 (d, d, 2H, CH2 of pyrazole ring), 3.93 (d, d, 1H, CH of pyrazole ring), 4.09 (q, 2H, CH2), 6.77–7.99 (m, 7H, Ar-H), 10.44 (s, 1H, OH). Anal. calcd for C17H18N2O3S (330.40): C, 61.80; H, 5.49; N, 8.48; found: C, 61.65; H, 5.45; N, 8.57.
Yield 66%; brown crystal; mp 158–160 °C (EtOH); IR (cm−1) ν: 3400 (OH), 3335, 3255 (NH2), 3106 (NH), 2800 (CH aliphatic), 1694 (CO), 1595 (CN); 1H-NMR: 3.06 (d, d, 2H, CH2 of pyrazole), 3.90 (d, d, 1H, CH of pyrazole), 5.15 (s, 2H, CH2), 6.72 (s, 2H, NH2), 6.79–7.844 (m, 11H, H-Ar), 9.70 (s, 1H, NH), 10.80 (s, 1H, OH). Anal. calcd for C21H20N4O4S2 (456.54): C, 55.25; H, 4.42; N, 12.27; found: C, 55.09; H, 4.33; N, 12.38.
All the newly synthesized 4-thiophenyl-pyrazole, pyridine, and pyrimidine derivatives were sketched using the ChemDraw and transferred to the MOE window, optimized for partial charges, and energy minimized as previously reported.53 Then, the target two proteins (EGFR and VEGFR-2) were extracted from the PDB (IDs: 2RGP54 and 2OH4 (ref. 55)), respectively. Each protein was corrected, 3D hydrogenated, and energy minimized as before.56 Finally, two different docking processes were carried out to evaluate the binding affinities of the new candidates toward both EGFR and VEGFR-2 receptor pockets, respectively. The co-crystallized inhibitors were inserted as reference standards and the program specifications were adjusted as previously mentioned.57
Full geometry optimization was performed using 6-31+G(d,p) as a basis set to generate the optimized structures and ground state properties of the studied compounds. The basis set 6-31+G(d,p) was augmented by ‘d’ polarization functions on heavy atoms and ‘p’ polarization functions on hydrogen atoms. Also, the diffuse functions for both hydrogen and heavy atoms were used.
To predict the chemical reactivity, some theoretical descriptors related to conceptual DFT have been determined for compound 10b and reference drugs. The lowest unoccupied (vacant) molecular orbital (LUMO) energy (ELUMO), the highest occupied molecular orbital (HOMO) energy (EHOMO), the electronegativity (χ), the global softness (S), and hardness (η) descriptors were all determined from the optimized molecules. It should be noted that the descriptors related to frontier molecular orbitals FMO have been calculated in a very simple way in the context of the Koopmans approximation.60
Footnotes |
† Electronic supplementary information (ESI) available: Elemental analysis tables, IR, NMR, and mass spectra of all target compounds. See DOI: https://doi.org/10.1039/d3ra00416c |
‡ Equal contribution. |
This journal is © The Royal Society of Chemistry 2023 |